WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Prostate Cancer Efficacy Endpoints_v10, COVARIATES include Serum testosterone level, - CR - PR differentiated into Confirmation Date, Anatomical region instantiated by -Lung -CNS -Liver -Adrenal (L, R) -Lymph nodes -Other, COVARIATES include Type of Progression, Non-opiate Administration measured at Start Date, Bone Scintigraphy provides Image readability, Type instantiated by - androgen receptor antagonist - androgen synthesis inhibitor - other, Target lesion evaluated by Quantitative assessment, Hormonal intervention has attributes Duration of administration, OVERALL RESPONSE derived from Sponsor specified Response Criteria (e.g. RECIST), Functional Status Impairment measured with Functional Status Assessment Tool, Sum of longest diameters (SLD) has component LD (axial plane) for target lesion, Time-To-Event efficacy endpoints include Time to Initiation of Chemotherapy, Baseline lesion(s) identified by Baseline lesion ID, -Complete Response (CR) -Non-CR/non-PD -Not all evaluated -Non-PD -PD summarized into OVERALL RESPONSE, T U M O R R E S P O N S E is assessed with -MRI -CT, Progression Free Survival (PFS) includes Radiographic Progression Free Survival (rPFS), Non-target lesion evaluated by Qualitative Assessment, New lesion identified by Organ specific lesion ID, OVERALL RESPONSE have response options -SD -PD -NE (inevaluable)